glycine has been researched along with Dyskinesia, Medication-Induced in 13 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "While Parkinson's disease (PD) phenotype in leucine-rich repeat kinase 2 gene (LRRK2)-associated and sporadic PD seems similar, there is paucity of data on the possible effect of mutations in LRRK2 on response to and complications of dopaminergic therapy." | 1.38 | Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation. ( Cohen, OS; Friedman, E; Hassin-Baer, S; Inzelberg, R; Kaplan, N; Korczyn, AD; Kozlova, E; Rosset, S; Vituri, A; Yahalom, G, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 1 (7.69) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 3 (23.08) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bourque, M | 3 |
| Grégoire, L | 3 |
| Patel, W | 3 |
| Dickens, D | 3 |
| Snodgrass, R | 3 |
| Di Paolo, T | 3 |
| Solís, O | 1 |
| García-Sanz, P | 1 |
| Herranz, AS | 1 |
| Asensio, MJ | 1 |
| Moratalla, R | 1 |
| Paus, S | 1 |
| Gadow, F | 1 |
| Knapp, M | 1 |
| Klein, C | 1 |
| Klockgether, T | 1 |
| Wüllner, U | 1 |
| Johnson, KA | 1 |
| Jones, CK | 1 |
| Tantawy, MN | 1 |
| Bubser, M | 1 |
| Marvanova, M | 1 |
| Ansari, MS | 1 |
| Baldwin, RM | 1 |
| Conn, PJ | 1 |
| Niswender, CM | 1 |
| Yahalom, G | 1 |
| Kaplan, N | 1 |
| Vituri, A | 1 |
| Cohen, OS | 1 |
| Inzelberg, R | 1 |
| Kozlova, E | 1 |
| Korczyn, AD | 1 |
| Rosset, S | 1 |
| Friedman, E | 1 |
| Hassin-Baer, S | 1 |
| Zhang, Z | 1 |
| Hou, G | 1 |
| Zhang, X | 2 |
| Yao, H | 1 |
| Sha, W | 1 |
| Shoham, S | 1 |
| Mazeh, H | 1 |
| Javitt, DC | 1 |
| Heresco-Levy, U | 2 |
| Bakker, PR | 1 |
| van Harten, PN | 1 |
| van Os, J | 1 |
| Hammond, EJ | 1 |
| Wilder, BJ | 1 |
| Bruni, J | 1 |
| Segman, R | 1 |
| Neeman, T | 1 |
| Finkel, B | 1 |
| Karagichev, L | 1 |
| Schlafman, M | 1 |
| Dorevitch, A | 1 |
| Yakir, A | 1 |
| Lerner, A | 1 |
| Shelevoy, A | 1 |
| Lerer, B | 2 |
| Dawson, L | 1 |
| Chadha, A | 1 |
| Megalou, M | 1 |
| Duty, S | 1 |
| Segman, RH | 1 |
| Fangerau, H | 1 |
| Daly, AK | 1 |
| Basile, VS | 1 |
| Cavallaro, R | 1 |
| Aschauer, HN | 1 |
| McCreadie, RG | 1 |
| Ohlraun, S | 1 |
| Ferrier, N | 1 |
| Masellis, M | 1 |
| Verga, M | 1 |
| Scharfetter, J | 1 |
| Rietschel, M | 1 |
| Lovlie, R | 1 |
| Levy, UH | 1 |
| Meltzer, HY | 1 |
| Kennedy, JL | 1 |
| Steen, VM | 1 |
| Macciardi, F | 1 |
| Vamvakidès, A | 1 |
3 reviews available for glycine and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Central actions of valproic acid in man and in experimental models of epilepsy.
Topics: 4-Aminobutyrate Transaminase; Action Potentials; Alcohol Oxidoreductases; Aldehyde Oxidoreductases; | 1981 |
Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism.
Topics: Adult; Aged; Analysis of Variance; Chi-Square Distribution; Confidence Intervals; Dyskinesia, Drug-I | 2002 |
[Effect of glycine-steatamide or glutamic acid palmitamide on oral dyskinesia, obtained by a single administration of haloperidol combined with GABA-linoleamide in rats].
Topics: Animals; Drug Combinations; Dyskinesia, Drug-Induced; Female; gamma-Aminobutyric Acid; Glutamates; G | 1988 |
10 other studies available for glycine and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
AV-101, a Pro-Drug Antagonist at the NMDA Receptor Glycine Site, Reduces L-Dopa Induced Dyskinesias in MPTP Monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amantadine; Animals; Antiparkinson Agents; Dyskinesia, | 2022 |
L-DOPA Reverses the Increased Free Amino Acids Tissue Levels Induced by Dopamine Depletion and Rises GABA and Tyrosine in the Striatum.
Topics: Amino Acids; Animals; Aspartic Acid; Corpus Striatum; Dopamine; Dyskinesia, Drug-Induced; Forelimb; | 2016 |
Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Community Networks; Dyskinesia, Drug-Induced; Female; | 2009 |
The metabotropic glutamate receptor 8 agonist (S)-3,4-DCPG reverses motor deficits in prolonged but not acute models of Parkinson's disease.
Topics: Aminobutyrates; Animals; Benzoates; Catalepsy; Disease Models, Animal; Dopamine; Dopamine D2 Recepto | 2013 |
Dyskinesias in patients with Parkinson's disease: effect of the leucine-rich repeat kinase 2 (LRRK2) G2019S mutation.
Topics: Adult; Aged; Aged, 80 and over; DNA Mutational Analysis; Dyskinesia, Drug-Induced; Female; Gene Freq | 2012 |
[Pharmacogenetic assessment of antipsychotic-induced tardive dyskinesia: contribution of 5-hydroxytryptamine 2C receptor gene and of a combination of dopamine D3 variant allele (Gly) and MnSOD wild allele (Val)].
Topics: Aged; Alleles; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Gene Frequency; Genetic Varia | 2003 |
Glycine and D-cycloserine attenuate vacuous chewing movements in a rat model of tardive dyskinesia.
Topics: Animals; Cycloserine; Disease Models, Animal; Dyskinesia, Drug-Induced; Glycine; Haloperidol; Mastic | 2004 |
Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis.
Topics: Alleles; Antipsychotic Agents; Chi-Square Distribution; Dyskinesia, Drug-Induced; Female; Glycine; H | 2006 |
Genotypic association between the dopamine D3 receptor and tardive dyskinesia in chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Dyskinesia, Drug-Induced; Female; Genotype; Glycine; Humans; Israel; Je | 1999 |
The group II metabotropic glutamate receptor agonist, DCG-IV, alleviates akinesia following intranigral or intraventricular administration in the reserpine-treated rat.
Topics: Animals; Anticonvulsants; Antipsychotic Agents; Cyclopropanes; Dyskinesia, Drug-Induced; Glycine; In | 2000 |